Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Non-Current Deffered Revenue (2023 - 2025)

Coya Therapeutics (COYA) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 11.07% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 11.07% year-over-year, with the annual reading at $1.1 million for FY2025, 11.07% up from the prior year.
  • Non-Current Deffered Revenue hit $1.1 million in Q4 2025 for Coya Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q3 2024 to a low of $574685.0 in Q4 2023.
  • Historically, Non-Current Deffered Revenue has averaged $861961.0 across 3 years, with a median of $856650.0 in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 64.52% in 2024 and later dropped 25.16% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $574685.0 in 2023, then skyrocketed by 64.52% to $945447.0 in 2024, then increased by 11.07% to $1.1 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for COYA at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $641158.0 in Q2 2025.